Chinese Medical Sciences Journal ›› 2011, Vol. 26 ›› Issue (2): 119-125.doi: 10.1016/S1001-9294(11)60031-X
• Original Article • Previous Articles Next Articles
C-peptide and Diabetic Encephalopathy
Xiao-jun Cai1*, Hui-qin Xu2, and Yi Lu1
- 1Department of Pharmacy, Wuxi People’s Hospital, Wuxi , Jiangsu 214023, China
2Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing 210029, China
-
Received:2011-06-24Revised:2011-06-24Online:2011-06-24Published:2011-06-24
Cite this article
Xiao-jun Cai*, Hui-qin Xu, and Yi Lu . C-peptide and Diabetic Encephalopathy[J].Chinese Medical Sciences Journal, 2011, 26(2): 119-125.
share this article
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| 1. | van Dieren S, Beulens JW, van derSchouw YT, et al. The global burden of diabetes and its complications: anemerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17:S3-8. |
| 2. | Mastrocola R, Restivo F,Vercellinatto I, et al. Oxidative and nitrosative stress in brain mitochondriaof diabetic rats. J Endocrinol 2005; 187:37-44. |
| 3. | Duchen MR. Role of mitochondria inhealth and disease. Diabetes 2004; 53:S96-102. |
| 4. | Aragno M, Parola S, Brignardello E,et al. Dehydroepiandrosterone prevents oxidative injury induced by transientischemia reperfusion in the brain of diabetic rats. Diabetes 2000; 49:1924-31. |
| 5. | Aragno M, Parola S, Tamagno E, etal. Oxidative derangement in rat synaptosomes induced by hyperglycaemia:restorativeeffect of dehydroepiandrosterone treatment. Biochem Pharmacol 2000; 60:389-95. |
| 6. | Aragno M, Mastrocola R, BrignardelloE, et al. Dehydroepiandrosterone modulates nuclear factor-kB activation inhippocampus of diabetic rats. Endocrinology 2002; 143:3250-8. |
| 7. | Arvanitakis Z, Wilson RS, BieniasJL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitivefunction. Arch Neurol 2004; 61:661-6. |
| 8. | Biessels GJ, van der Heide LP, KamalA, et a1. Aging and diabetes: implications for brain function. Eur J Pharmacol2002; 441:1-14. |
| 9. | Ma F, Wang T, Yin J, et al. Acase-control study on the influencing factors to mild cognitive impairmentamong the community-based elderly population. Zhonghua Liu Xing Bing Xue Za Zhi2008; 29:873-7. |
| 10 | Blanz BJ, Rensch-Riemann BS,Fritz-Sigmund DI, et al. IDDM is a risk factor for adolescent psychiatric disorders.Diabetes Care 1993; 16:1579-87. |
| 11 | Pulsinelli WA, Levy DE, Sigsbee B, et al. Increaseddamage after ischemic stroke in patients with hyperglycemia with or without establisheddiabetes mellitus. The Am J Med 1983; 74:540-4. |
| 12 | Sima AA. Encephalopathies: theemerging diabetic complications. Acta Diabetol 2010; 47:279-93. |
| 13 | van Harten B, de Leeuw FE, WeinsteinHC, et al. Brain imaging in patients with diabetes: a systematic review.Diabetes Care 2006; 29:2539-48. |
| 14 | Li ZG, Sima AA. C-peptide andcentral nervous system complications in diabetes. Exp Diabesity Res 2004;5:79-90. |
| 15 | Kramer L, Fasching P, Madl C, et al.Previous episodes of hypoglycemic coma are not associated with permanentcognitive brain dysfunction in IDDM patients on intensive insulin treatment.Diabetes 1998; 47:1909-14. |
| 16 | Schoenle EJ, Schoenle D, Molinari L,et al. Impaired intellectual development in children with type I diabetes:association with HbA(1c), age at diagnosis and sex. Diabetologia2002; 45:108-14. |
| 17 | Laing SP, Swerdlow AJ, Carpenter LM,et al. Mortality from cerebrovascular disease in a cohort of 23 000 patientswith insulin-treated diabetes. Stroke 2003; 34:418-21. |
| 18 | Awad N, Gagnon M, Messier C. Therelationship between impaired glucose tolerance, type 2 diabetes, and cognitivefunction. J Clin Exp Neuropsychol 2004; 26:1044-80. |
| 19 | Ryan CM, Geckle MO.Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes.Diabetes Care 2000; 23:1486-93. |
| 20 | Ryan CM, Geckle M. Why is learningand memory dysfunction in type 2 diabetes limited to older adults? DiabetesMetab Res Rev 2000; 16:308-15. |
| 21 | Manschot SM, Brands AM, van derGrond J, et al. Brain magnetic resonance imaging correlates of impaired cognitionin patients with type 2 diabetes. Diabetes 2006; 55:1106-13. |
| 22 | S Roriz-Filho J, Sá-Roriz TM, RossetI, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009;1792:432-43. |
| 23 | Kothari V, Stevens RJ, Adler AI, etal. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK ProspectiveDiabetes Study risk engine. Stroke 2002; 33:1776-81. |
| 24 | Brownlee M. Biochemistry andmolecular cell biology of diabetic complications. Nature 2001; 414:813-20. |
| 25 | Aszalós Z. Cerebral complications ofdiabetes mellitus. Orv Hetil 2008; 2:19-27. |
| 26 | Kern W, Peters A, Fruehwald-SchultesB, et al. Improving influence of insulin on cognitive functions in humans.Neuroendocrinology 2001; 74:270-80. |
| 27 | Cole AR, Astell A, Green C, et al.Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007;31:1046-63. |
| 28 | Okereke O, Hankinson SE, Hu FB, etal. Plasma C peptide level and cognitive function among older women withoutdiabetes mellitus. Arch Intern Med 2005; 165:1651-6. |
| 29 | Zhao WQ, Alkon DL. Role of insulinand insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177:125-34. |
| 30 | Li ZG, Zhang W, Sima AA. C-peptideenhances insulin-mediated cell growth and protection against high glucoseinduced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003; 19:375-85. |
| 31 | Sima AA, Zhang W, Li ZG, et al. Theeffects of C-peptide on type 1 diabetic polyneuropathies and encephalopathy inthe BB/Wor-rat. Exp Diabetes Res 2008; 2008:1-13. |
| 32 | Nordquist L, Johansson M. Proinsulin C-peptide: friend or foe inthe development of diabetes-associated complications? VascHealth Risk Manag 2008; 4:1283-8. |
| 33 | Hanafusa T, Imagawa A, Iwahashi H,et al. Report of the committee of the Japan diabetes society on researchon fulminant type 1 diabetes mellitus: analysis of HLA serotype and diabeticmicroangiopathy. J JapanDiabet Soc 2007; 50:825-32. |
| 34 | Kim BY, Jung CH, Mok JO, et al.Association between serum C-peptide levels and chronic microvascular complicationsin Korean type 2 diabetic patients. Acta Diabetol 2011 Jan [cited 2011Feb 21]. Available from:http://www. springerlink. com/content/q3t4627476v 761g 7/ |
| 35 | Sima AA, Zhang W, Xu G, et al. A comparisonof diabetic polyneuropathy in type 2 diabetic BBZDR/Wor-rats and in type 1diabetic BB/Wor-rats. Diabetologia 2000; 43:786- 93. |
| 36 | Stevens MJ, Zhang W, Li F, et al.C-peptide corrects endoneurial blood flow but not oxidative stress in type 1BB/Wor-rats. Am J Physiol Endocrinol Metab 2004; 287: E497-505. |
| 37 | Wahren J, Ekberg K, J?rnvall H.C-peptide is a bioactive peptide. Diabetologia 2007; 50:503-9. |
| 38 | Rigler R,Pramanik A, Jonasson P, et al. Specific binding of proinsulin C-peptide tohuman cell membranes. Proc Nat Acad Sci U S A 1999; 96:13318-23. |
| 39 | Kamiya H, Zhang W, Ekberg K, et al.C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes 2006;55:3581-7. |
| 40 | Sima AA.New insights into the metabolic and molecular basis for diabetic neuropathy.Cell Mol Life Sci 2003; 60:2445-64. |
| 41 | Sima AA.C-peptide and diabetic neuropathy. Expert Opin Investig Drugs 2003; 12:1471-88. |
| 42 | Grunberger G, Qiang X, Li ZG, et al. Molecular basis forthe insulinomimetic effects of C-peptide. Diabetologia 2001; 44:1247-57. |
| 43 | Ekberg K, Brismar T, Johansson BL,et al. Amelioration of sensory nerve dysfunction by C-peptide in patients withtype 1 diabetes. Diabetes 2003; 52:536-41. |
| 44 | Ekberg K, Brismar T, Johansson BL,et al. C-peptide replacement therapy and sensory nerve function in type 1diabetic neuropathy. Diabetes Care 2007; 30:71-6. |
| 45 | Samneg?rd B, Jacobson SH, Jaremko G,et al. C-peptide prevents glomerular hypertrophy and mesangial matrix expansionin diabetic rats. Nephrol Dial Transplant 2005; 20:532-8. |
| 46 | Kamikawa A, Ishii T, Shimada K, etal. Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renalendothelial nitric oxide synthase in rats. Diabetes Metab Res Rev 2008;24:331-8. |
| 47 | Sima AA, Zhang W, Grunberger G. Type1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004; 5:65-77. |
| 48 | Walcher D, Marx N. C-Peptide in thevessel wall. Rev Diabet Stud 2009; 6:180-6. |
| 49 | Kobayashi Y, Naruse K, Hamada Y, et al. Human proinsulinC-peptide prevents proliferation of rat aortic smooth muscle cells cultured inhigh-glucose conditions. Diabetologia 2005; 48:2396-401. |
| 50 | Stettler C, Allemann S, Jüni P, etal. Glycemic control and macrovascular disease in types 1 and 2 diabetesmellitus: meta-analysis of randomized trials. Am Heart J 2006; 152:27-38. |
| 51 | Maki T, Otsu I, O’Neil JJ, et al. Treatment ofdiabetes by xenogeneic islets without immunosuppression. Use of a vascularizedbioartificial pancreas. Diabetes 1996; 45: 342-7. |
| 52 | Hansen A, Johansson BL, Wahren J, etal. C-peptide exerts beneficial effects on myocardial blood flow and functionin patients with type 1 diabetes. Diabetes 2002; 51:3077- 82. |
| 53 | Brands AM, RP Kessels, de Haan EH,et al. Cerebral dysfunction in type 1 diabetes: effects of insulin, vascularrisk factors and blood-glucose levels. Eur J Pharmacol 2004; 490:159-68. |
| [1] | Sheng-da Liu*,Qing-min Shen,Chun-feng Lv. Reversible Posterior Leukoencephalopathy Syndrome in Children with Nephrotic Syndrome: a Case Report [J]. Chinese Medical Sciences Journal, 2014, 29(1): 55-57. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
